Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$39.98K$39.98K−26.0% vs Q3 2019 Net Income-$1.07M-$1.07MN/M vs Q3 2019 EPS Diluted-$0.07-$0.07N/M vs Q3 2019 Gross Profit$39,220−13.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$96,673N/M Margins · derivedGross margin98.1%+14.6 pt vs Q3 2019
Operating margin-2368.2%+21.3 pt vs Q3 2019
Net margin-2673.9%−71.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 19, 2020 · 50 d after period end